Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stemtech (STEK) EBITDA (2020 - 2025)

Stemtech's EBITDA history spans 6 years, with the latest figure at -$812541.0 for Q3 2025.

  • For Q3 2025, EBITDA rose 63.99% year-over-year to -$812541.0; the TTM value through Sep 2025 reached -$1.7 million, up 74.2%, while the annual FY2024 figure was -$4.1 million, 17.74% up from the prior year.
  • EBITDA for Q3 2025 was -$812541.0 at Stemtech, up from -$1.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $17.0 million in Q3 2022 and bottomed at -$24.6 million in Q2 2022.
  • The 5-year median for EBITDA is -$773300.0 (2025), against an average of -$1.4 million.
  • The largest YoY upside for EBITDA was 393.92% in 2022 against a maximum downside of 8215.81% in 2022.
  • A 5-year view of EBITDA shows it stood at -$584502.0 in 2021, then soared by 84.14% to -$92699.0 in 2022, then crashed by 1208.61% to -$1.2 million in 2023, then surged by 192.1% to $1.1 million in 2024, then tumbled by 172.73% to -$812541.0 in 2025.
  • Per Business Quant, the three most recent readings for STEK's EBITDA are -$812541.0 (Q3 2025), -$1.2 million (Q2 2025), and -$773300.0 (Q1 2025).